Julia T. Wang
YOU?
Author Swipe
View article: Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
View article: Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Batch specific co-expression analysis.
View article: Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
List of recurrent mutations with potential utility as neoantigens
View article: Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
View article: Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence
Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence Open
Age-related decline in immune function increases susceptibility to hematologic malignancies. Although bone marrow (BM) orchestrates immunity, age-related changes in the marrow microenvironment are not well understood, partially due to chal…
View article: Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer
Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer Open
View article: Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
View article: Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Batch specific co-expression analysis.
View article: Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
View article: Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
supplementary figures
View article: Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Batch specific co-expression analysis.
View article: Data from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Data from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone m…
View article: Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
supplementary figures
View article: Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
List of recurrent mutations with potential utility as neoantigens
View article: Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
View article: Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
List of recurrent mutations with potential utility as neoantigens
View article: Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
View article: A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma Open
Multiple Myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sen…
View article: Cancer-associated fibroblast-derived Dickkopf-1 suppresses NK cell cytotoxicity in breast cancer
Cancer-associated fibroblast-derived Dickkopf-1 suppresses NK cell cytotoxicity in breast cancer Open
View article: #15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
#15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
View article: Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
supplementary figures
View article: Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.